NTLA - Intellia Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5595.49M
Enterprise Value 3379.09M
Trailing P/E N/A
Forward P/E 1-4.17
PEG Ratio (5 yr expected) 1-0.17
Price/Sales (ttm)13.82
Price/Book (mrq)2.19
Enterprise Value/Revenue 38.80
Enterprise Value/EBITDA 6-3.76

Trading Information

Stock Price History

Beta (5Y Monthly) 2.14
52-Week Change 3-29.44%
S&P500 52-Week Change 3-8.39%
52 Week High 319.00
52 Week Low 39.18
50-Day Moving Average 313.04
200-Day Moving Average 313.74

Share Statistics

Avg Vol (3 month) 3761.19k
Avg Vol (10 day) 3624.88k
Shares Outstanding 550.51M
Float 40.74M
% Held by Insiders 119.34%
% Held by Institutions 177.41%
Shares Short (Mar 12, 2020) 410.66M
Short Ratio (Mar 12, 2020) 411.4
Short % of Float (Mar 12, 2020) 428.16%
Short % of Shares Outstanding (Mar 12, 2020) 421.10%
Shares Short (prior month Feb 13, 2020) 410.38M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2019
Most Recent Quarter (mrq)Dec 30, 2019

Profitability

Profit Margin -230.92%
Operating Margin (ttm)-246.78%

Management Effectiveness

Return on Assets (ttm)-19.51%
Return on Equity (ttm)-36.34%

Income Statement

Revenue (ttm)43.1M
Revenue Per Share (ttm)0.91
Quarterly Revenue Growth (yoy)38.80%
Gross Profit (ttm)-65.31M
EBITDA -100.78M
Net Income Avi to Common (ttm)-99.53M
Diluted EPS (ttm)-2.11
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)279.73M
Total Cash Per Share (mrq)5.54
Total Debt (mrq)18.38M
Total Debt/Equity (mrq)6.81
Current Ratio (mrq)8.12
Book Value Per Share (mrq)5.38

Cash Flow Statement

Operating Cash Flow (ttm)-103.24M
Levered Free Cash Flow (ttm)-62.12M